Ingredient or product comparison
Hair Loss Peptides 2026 Update: Clinical Evidence Comparison
GHK-Cu (copper peptide) Lysyl oxidase activation, VEGF upregulation, collagen synthesis Phase IIb (completed) Terminal hair density increase at 24 weeks +14.3% vs +2.1% (p<0.001) Microneedling + topical application twice weekly shows reproducible benefit TB-4
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu (copper peptide)
- Lysyl oxidase activation, VEGF upregulation, collagen synthesis
- Phase IIb (completed)
- Terminal hair density increase at 24 weeks
- +14.3% vs +2.1% (p<0.001)
- Microneedling + topical application twice weekly shows reproducible benefit
- TB-4 / TB500 fragment
- Stem cell recruitment, bulge activation
- Phase IIa (failed endpoint)
- Hair density, shaft diameter
- No significant difference vs placebo
- Insufficient evidence for androgenetic alopecia use
- BPC-157
- Anti-inflammatory, cytokine modulation
- Phase I (ongoing)
- Safety, preliminary density signal
- Data pending Q2 2027
- Too early for clinical recommendation
- PTD-DBM (sonic hedgehog pathway)
- Follicle progenitor signaling
- Preclinical only
- N/A
- Mouse model data only
- No human data. Speculative mechanism